{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:17:07Z","timestamp":1792819027854,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1053\/j.seminhematol.2023.03.009","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T07:24:52Z","timestamp":1681975492000},"page":"97-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria"],"prefix":"10.1053","volume":"60","author":[{"given":"Steven P.","family":"Treon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Garcia-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Benevolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger G.","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1053\/j.seminhematol.2023.03.009_bib0001","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus recommendations from the second International Workshop on Waldenstrom's Macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.03.009_bib0002","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.12102","article-title":"Response assessment in Waldenstr\u00f6m macroglobulinaemia: update from the VIth International Workshop","volume":"160","author":"Owen","year":"2013","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2023.03.009_bib0003","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2023.03.009_bib0004","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.19.02314","article-title":"Genomic Landscape of Waldenstr\u00f6m Macroglobulinemia and Its Impact on Treatment Strategies","volume":"38","author":"Treon","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2023.03.009_bib0005","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","article-title":"MYD88 L265P in Waldenstr\u00f6m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction","volume":"121","author":"Xu","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2023.03.009_bib0006","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/leu.2013.62","article-title":"MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstr\u00f6m's macroglobulinemia","volume":"27","author":"Jimenez","year":"2013","journal-title":"Leukemia"},{"issue":"13","key":"10.1053\/j.seminhematol.2023.03.009_bib0007","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2013-07-513366","article-title":"MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance","volume":"122","author":"Varettoni","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.03.009_bib0008","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/bjh.13897","article-title":"Clonal architecture of CXCR4 WHIM-like mutations in Waldenstr\u00f6m macroglobulinaemia","volume":"172","author":"Xu","year":"2016","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2023.03.009_bib0009","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.3324\/haematol.2017.172718","article-title":"Pattern of somatic mutations in patients with Waldenstr\u00f6m macroglobulinemia or IgM monoclonal gammopathy of undetermined significance","volume":"102","author":"Varettoni","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.03.009_bib0010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.18502","article-title":"Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenstr\u00f6m macroglobulinaemia","volume":"200","author":"Moreno","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1053\/j.seminhematol.2023.03.009_bib0011","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/bjh.15049","article-title":"MYD88 wild-type Waldenstrom macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival","volume":"180","author":"Treon","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"18","key":"10.1053\/j.seminhematol.2023.03.009_bib0012","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","article-title":"International prognostic scoring system for Waldenstrom macroglobulinemia","volume":"113","author":"Morel","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.03.009_bib0013","first-page":"1211","article-title":"Waldenstrom's Macroglobulinemia\/Lymphoplasmacytic Lymphoma, Version 2.2013. Featured updates to the NCCN Guidelines","volume":"10","author":"Anderson","year":"2012","journal-title":"JNCCN"},{"issue":"25","key":"10.1053\/j.seminhematol.2023.03.009_bib0014","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstrom's macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.03.009_bib0015","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: a single-arm, multicentre, phase 2 study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Hematol"},{"issue":"18","key":"10.1053\/j.seminhematol.2023.03.009_bib0016","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood.2020006449","article-title":"Zanubrutinib for the treatment of patients with Waldenstr\u00f6m macroglobulinemia: 3 years of follow-up","volume":"136","author":"Trotman","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2023.03.009_bib0017","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/bloodadvances.2020003895","article-title":"Obinutuzumab and idelalisib in symptomatic patients with relapsed\/refractory Waldenstr\u00f6m macroglobulinemia","volume":"5","author":"Tomowiak","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.03.009_bib0018","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.21.00105","article-title":"Combining ixazomib with subcutaneous rituximab and dexamethasone in relapsed or refractory Waldenstr\u00f6m's Macroglobulinemia: final analysis of the phase I\/II HOVON124\/ECWM-R2 study","volume":"40","author":"Kersten","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.03.009_bib0019","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.01805","article-title":"Bortezomib-dexamethasone, rituximab, and cyclophosphamide as first-line treatment for Waldenstrom's macroglobulinemia: a prospectively randomized trial of the European Consortium for Waldenstrom's macroglobulinemia","author":"Buske","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1053\/j.seminhematol.2023.03.009_bib0020","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1053\/j.seminhematol.2023.03.009_bib0021","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib monotherapy in symptomatic, treatment-na\u00efve patients with Waldenstr\u00f6m Macroglobulinemia","volume":"36","author":"Treon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1053\/j.seminhematol.2023.03.009_bib0022","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1182\/bloodadvances.2020001963","article-title":"Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstr\u00f6m macroglobulinemia: long-term follow-up","volume":"4","author":"Castillo","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.03.009_bib0023","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.21.01194","article-title":"Venetoclax in previously treated Waldenstrom's macroglobulinemia","volume":"40","author":"Castillo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1053\/j.seminhematol.2023.03.009_bib0024","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1182\/blood-2022-155610","article-title":"Ibrutinib and venetoclax in previously untreated Waldenstr\u00f6m macroglobulinemia","volume":"140","author":"Castillo","year":"2022","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.seminhematol.2023.03.009_bib0025","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2023.03.009_bib0026","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1182\/bloodadvances.2020003010","article-title":"Zanubrutinib for the treatment of MYD88 wild-type Waldenstr\u00f6m macroglobulinemia: a substudy of the phase 3 ASPEN trial","volume":"4","author":"Dimopoulos","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2023.03.009_bib0027","series-title":"Proc. of the 11th International Workshop on Waldenstrom's macroglobulinemia","article-title":"ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenstr\u00f6m macroglobulinemia","author":"Dimopoulos","year":"2022"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.03.009_bib0028","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/annonc\/mdi022","article-title":"Extended rituximab therapy in Waldenstrom's macroglobulinemia","volume":"16","author":"Treon","year":"2005","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1053\/j.seminhematol.2023.03.009_bib0029","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1200\/JCO.2007.10.9926","article-title":"Primary treatment of Waldenstr\u00f6m macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide","volume":"25","author":"Dimopoulos","year":"2007","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1053\/j.seminhematol.2023.03.009_bib0030","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1182\/blood-2008-09-177329","article-title":"Long-term outcomes to fludarabine and rituximab in Waldenstrom Macroglobulinemia","volume":"113","author":"Treon","year":"2009","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2023.03.009_bib0031","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","article-title":"Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180","volume":"27","author":"Treon","year":"2009","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1053\/j.seminhematol.2023.03.009_bib0032","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","article-title":"Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)","volume":"122","author":"Dimopoulos","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2023.03.009_bib0033","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1158\/1078-0432.CCR-16-1918","article-title":"Prospective, multicenter clinical trial of everolimus as primary therapy in Waldenstrom macroglobulinemia","volume":"23","author":"Treon","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1053\/j.seminhematol.2023.03.009_bib0034","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2009-05-174359","article-title":"How I treat Waldenstrom macroglobulinemia","volume":"114","author":"Treon","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.03.009_bib0035","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/13506129.2015.1092433","article-title":"Clinical presentation and treatment responses in IgM-related AL amyloidosis","volume":"22","author":"Sissoko","year":"2015","journal-title":"Amyloid"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.03.009_bib0036","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41375-019-0667-6","article-title":"IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features","volume":"34","author":"Sidana","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.03.009_bib0037","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50038","article-title":"Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's macroglobulinemia","volume":"30","author":"Kyle","year":"2003","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.03.009_bib0038","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clml.2013.02.005","article-title":"Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenstr\u00f6m macroglobulinemia","volume":"13","author":"Kyle","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.03.009_bib0039","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.03.009_bib0040","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2002.09.039","article-title":"Treatment of Waldenstrom's macroglobulinemia with rituximab","volume":"20","author":"Dimopoulos","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2023.03.009_bib0041","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1002\/cncr.20658","article-title":"Initial immunoglobulin M \u2018flare\u2019 after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia","volume":"101","author":"Ghobrial","year":"2004","journal-title":"Cancer"},{"issue":"10","key":"10.1053\/j.seminhematol.2023.03.009_bib0042","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/annonc\/mdh403","article-title":"Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia","volume":"15","author":"Treon","year":"2004","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.03.009_bib0043","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1158\/1078-0432.CCR-08-0862","article-title":"Lenalidomide and rituximab in Waldenstrom's macroglobulinemia","volume":"15","author":"Treon","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.03.009_bib0044","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(16)30166-1","article-title":"A phase 2 study of ofatumumab in Waldenstr\u00f6m's macroglobulinaemia","volume":"4","author":"Furman","year":"2017","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2023.03.009_bib0045","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.3324\/haematol.2017.186908","article-title":"Ibrutinib withdrawal symptoms in patients with Waldenstr\u00f6m macroglobulinemia","volume":"103","author":"Castillo","year":"2018","journal-title":"Haematologica"},{"issue":"3","key":"10.1053\/j.seminhematol.2023.03.009_bib0046","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3324\/haematol.2013.091702","article-title":"Primary cold-agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma","volume":"99","author":"Randen","year":"2014","journal-title":"Haematologica"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196323000379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196323000379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:29:22Z","timestamp":1758522562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196323000379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0037196323000379"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.03.009","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}